How Omega-3 Supplements May Help Control Blood Pressure in Pregnant Women with High blood pressure

Effect of Omega-3 Supplementation on Blood Pressure Regulation in Pregnant Women with Gestational Hypertension - Nil

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/093347

Enrollment

Registered

2025-08-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O132- Gestational [pregnancy-induced] hypertension without significant proteinuria, second trimester

Interventions

Intervention1: Ajuvant Therapy: Omega-3 fatty acids 1300mg, once daily for three months Control Intervention1: Omega-3 Fatty Acids: DHA 350 EPA 550 BRAND NAME: WOW LIFE

Eligibility

Inclusion criteria

Inclusion criteria: 18 - 40-year-old pregnant women. BP Greater Than or equal to 140 bar 90mmHg. After 20 weeks or 20-34 weeks of gestation. Singleton pregnancy. Newly diagnosed with HTN.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The expected outcome of this study is that the combination of labetalol and omega-3 fatty acids will result in greater blood pressure reduction Systolic BP 5- 10mmHg; Diastolic BP 2- 6mmHg compared to labetalol alone (Systolic BP 5- 8mmHg; Diastolic BP 2- 4mmHg) in pregnant women with gestational hypertensionTimepoint: One year	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactMr A Prathap

SWAMY VIVEKANANDHA MEDICAL COLLEGE HOSPITAL & RESEARCH INSTITUTE

nivethanabalakrishnan@yahoo.com9442581234

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026